Press-release for stocks related to biotech-bay for ppruy

| -42.24% | O: 2.52% H: 2.74% C: 2.74%
PPRUY | News | $36.03 -0.11% 330K

| -43.2% | O: 1.88% H: 1.04% C: 0.57%
PCVX | $60.65 -2.85% -2.93% 660K

| 69.42% | O: -0.52% H: 0.55% C: -1.06%
STRO M | $3.76 -1.05% -1.06% 770K

| -20.34% | O: -1.05% H: 2.86% C: -5.08%
vax-24 disease pneumococcal study phase 2

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -43.3% | O: -3.64% H: 3.09% C: 1.33%
PPRUY | News | $36.03 -0.11% 330K

| -43.19% | O: -1.68% H: 1.12% C: -0.58%
PCVX | $60.65 -2.85% -2.93% 660K

| 41.18% | O: -0.93% H: 1.96% C: 0.55%
STRO M | $3.76 -1.05% -1.06% 770K

| -38.91% | O: -1.13% H: 5.37% C: -0.98%
vax-24 fda clearance drug disease application pneumococcal

Chan Zuckerberg Initiative Announces Partnership to Advance Genomics Research at the Nation's Four Historically Black Medical Colleges
Published: 2022-09-19 (Crawled : 19:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -25.8% | O: -0.84% H: 4.83% C: 1.27%
PPRUY | News | $36.03 -0.11% 330K

| -27.37% | O: -1.81% H: 2.18% C: 2.09%
partnership research genomics

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -33.43% | O: 5.95% H: 0.0% C: -1.24%
PPRUY | News | $36.03 -0.11% 330K

| -35.01% | O: 1.46% H: 0.62% C: -0.53%
PCVX | $60.65 -2.85% -2.93% 660K

| 140.76% | O: 0.62% H: 0.13% C: -0.65%
STRO M | $3.76 -1.05% -1.06% 770K

| -34.03% | O: 0.69% H: 10.52% C: 6.72%
update results

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -34.46% | O: 0.0% H: 5.96% C: 2.52%
PPRUY | News | $36.03 -0.11% 330K

| -36.0% | O: 0.04% H: 1.21% C: 0.78%
PCVX | $60.65 -2.85% -2.93% 660K

| 154.92% | O: 1.43% H: 3.54% C: 3.14%
STRO M | $3.76 -1.05% -1.06% 770K

| -29.24% | O: 1.68% H: 1.28% C: 0.55%
vax-24 positive

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-09 (Crawled : 21:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -24.45% | O: -0.12% H: 0.5% C: -4.16%
PPRUY | News | $36.03 -0.11% 330K

| -25.34% | O: -2.22% H: 0.4% C: -1.38%
DHR | $236.36 -1.27% 0.0% 4.2M

| -3.55% | O: -1.74% H: 0.98% C: -2.24%
PCVX | $60.65 -2.85% -2.93% 660K

| 157.23% | O: -1.4% H: 2.32% C: -10.53%
STRO M | $3.76 -1.05% -1.06% 770K

| -33.57% | O: 1.05% H: 1.04% C: -12.98%
results

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Published: 2022-04-04 (Crawled : 13:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -42.56% | O: 3.35% H: 0.0% C: -3.24%
PPRUY | News | $36.03 -0.11% 330K

| -43.59% | O: 0.03% H: 1.08% C: 0.94%
PCVX | $60.65 -2.85% -2.93% 660K

| 162.2% | O: -0.8% H: 10.94% C: 7.96%
STRO M | $3.76 -1.05% -1.06% 770K

| -55.61% | O: 0.47% H: 3.37% C: 2.67%
vax-24 ongoing phase 1 phase 2

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -49.18% | O: 1.35% H: 0.69% C: -2.73%
PPRUY | News | $36.03 -0.11% 330K

| -50.24% | O: -3.29% H: 2.78% C: 0.27%
PCVX | $60.65 -2.85% -2.93% 660K

| 176.24% | O: -0.66% H: 3.83% C: 3.21%
STRO M | $3.76 -1.05% -1.06% 770K

| -57.21% | O: -1.13% H: 3.08% C: 1.59%
financial results report results

Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program
Published: 2022-01-18 (Crawled : 19:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -53.64% | O: -2.63% H: 1.5% C: 0.9%
PPRUY | News | $36.03 -0.11% 330K

| -52.91% | O: -0.22% H: 0.93% C: -0.64%
health therapeutics cel accelerator program program

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -55.66% | O: 2.64% H: 0.0% C: -0.39%
PPRUY | News | $36.03 -0.11% 330K

| -56.36% | O: -0.99% H: 0.0% C: -1.16%
PCVX | $60.65 -2.85% -2.93% 660K

| 161.1% | O: 4.14% H: 2.57% C: -1.0%
STRO M | $3.76 -1.05% -1.06% 770K

| -73.92% | O: -20.18% H: 0.0% C: -9.63%
vax-24 new drug fda clearance application drug disease fda clearance pneumococcal

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
Published: 2021-11-10 (Crawled : 23:00) - biospace.com/
PPRUF | News | $361.9 37.56% 4.3K

| -54.68% | O: -1.46% H: 0.0% C: -2.17%
PPRUY | News | $36.03 -0.11% 330K

| -54.52% | O: -3.0% H: 0.18% C: -1.12%
PCVX | $60.65 -2.85% -2.93% 660K

| 150.62% | O: -0.36% H: 1.57% C: -0.6%
STRO M | $3.76 -1.05% -1.06% 770K

| -82.47% | O: 0.32% H: 1.26% C: -0.78%
financial results results

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M

Commercial Services

INVO | $1.555 104.6% 51.13% 5M

Professional, Scientific, and T...

ISPC | $0.437 105.16% 49.53% 37M

WLGS | News | $0.92 84.0% 45.65% 1.6M

OST | $0.499 21.38% 45.26% 1.9M

XPON | News | $3.1 60.62% 37.74% 17M

TIRX | $0.7 44.39% 30.74% 58M

BNTC | News | $6.92 44.17% 30.64% 3.5M